Platelet Fc Receptor

Moore, A. Ulric; Nachman, Ralph L.

doi:10.1172/jci110118

Cited by 52 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 shows binding ofimmune complexes to control platelet proteins that were transferred to nitrocellulose. 2 Fig. 1), but GP 210 appeared to be altered or lost, since immune complex no longer bound to it.…”

Section: Resultsmentioning

confidence: 98%

“…(1) showed that binding ofaggregated IgG to platelets inhibits ristocetin-induced platelet agglutination, and suggested that the IgG complex interferes with ristocetin-induced binding ofF VIII:vWF to GP lb. Also, binding of keyhole limpet hemocyanin (KLH)-anti-KLH immune complex to platelets is blocked by prior platelet exposure to ristocetin and F VIII: vWF (2). This observation further implicates GP lb in immune complex binding.…”

Section: Introductionmentioning

confidence: 89%

“…Previous studies have suggested that platelet glycoprotein lb (GP lb)' functions as an Fc receptor (1,2). GP lb is a 170,000-molwt glycoprotein that binds von Willebrand factor (F VIII: vWF) when platelets are exposed to ristocetin (1).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Evidence that a 210,000-molecular-weight glycoprotein (GP 210) serves as a platelet Fc receptor.

Stricker¹,

Reyes²,

Corash³

et al. 1987

J. Clin. Invest.

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 89%

See 1 more Smart Citation

Evidence that a 210,000-molecular-weight glycoprotein (GP 210) serves as a platelet Fc receptor.

Stricker¹,

Reyes²,

Corash³

et al. 1987

J. Clin. Invest.

View full text Add to dashboard Cite

show abstract

Acute coronary occlusion and in-stent thrombosis in a patient with essential thrombocythemia

Turgut

Harjai

Edupuganti

et al. 1998

Cathet. Cardiovasc. Diagn.

View full text Add to dashboard Cite

Essential thrombocythemias. Clinical evolutionary and biological data

Bellucci

Janvier

Tobelem

et al. 1986

Cancer

249

117

View full text Add to dashboard Cite

This retrospective study reviewed 94 patients, aged 6 to 90 years, with thrombocythemia. The women/men ratio was 1.76. At onset or, less commonly, during the course of the disease, 45% of the patients presented hemorrhagic manifestations, 29% thrombotic complications, and only 14% the association of hemorrhage and thrombosis. The average platelet count was 1200 X 10(9)/1, with no difference according to sex or age. Platelet hypoaggregation was seen in practically all the cases (94%), although myelofibrosis was less frequent (54%). The frequency of hemorrhages increased when the platelet count was above 1000 X 10(9)/1 (P less than 0.01), but the occurrence of thrombosis was correlated neither with platelet count nor with thrombopathy. Survival time was lengthy: 80% of survival (standard error 6%) was observed at 100 months. Transformation to acute leukemia was observed in five patients. Because the disease course is most often prolonged, therapeutic measures must be conservative: anti-aggregating drugs in small doses, and chemotherapy beginning with nonalkylating agents.

show abstract

Platelet Fc Receptor

Abstract: A B S T R A C T The platelet

Cited by 52 publications

References 24 publications

Evidence that a 210,000-molecular-weight glycoprotein (GP 210) serves as a platelet Fc receptor.

Evidence that a 210,000-molecular-weight glycoprotein (GP 210) serves as a platelet Fc receptor.

Acute coronary occlusion and in-stent thrombosis in a patient with essential thrombocythemia

Essential thrombocythemias. Clinical evolutionary and biological data

Contact Info

Product

Resources

About